Supplementary Materials

The PDF file includes:

  • Fig. S1. SSc fibroblasts maintain profibrotic gene expression pathways.
  • Fig. S2. SSc fibroblasts actively transcribe TGFB2 mRNA.
  • Fig. S3. Nonlesional SSc fibroblasts exhibit profibrotic gene expression.
  • Fig. S4. Quantification of TGFB2 mRNA by in situ hybridization.
  • Fig. S5. mRNA in situ hybridization for TGFB isoform expression in SSc lesional skin.
  • Fig. S6. SSc fibroblasts exhibit increased chromatin accessibility in genes related to profibrotic pathways.
  • Fig. S7. TGFβ2-expressing cell lines contain unique predicted enhancers at the TGFB2 locus.
  • Fig. S8. TGFβ2 enhancer accessibility correlates with TGFB2 mRNA expression.
  • Fig. S9. TGFB2 enhancer is inactive in nonlesional SSc fibroblasts.
  • Fig. S10. The TGFB2 enhancer exhibits minimal H3K27me3 modification in lesional SSc fibroblasts.
  • Fig. S11. SSc fibroblasts exhibit high NF-κB signaling activity.
  • Fig. S12. TNFα induces TGFB2 enhancer activity in a NF-κB– and BRD4-dependent manner.
  • Fig. S13. siRNA knockdown of BRD4 abrogates BRD4 mRNA expression.
  • Fig. S14. JQ1 treatment reduces collagen content in SSc skin explants.
  • Fig. S15. TGFβ2 inhibition by JQ1 or siRNA induces MMP1 expression in SSc fibroblasts.
  • Table S1. Patient data on SSc skin biopsy donors and healthy volunteers.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (.txt format). Sanger sequencing results.
  • Data file S2 (Microsoft Excel format). Shapiro-Wilk test results for normally distributed datasets.